Cost-Effectiveness Of Ceritinib In The Treatment Of Previously Treated Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In The United Kingdom.
نویسندگان
چکیده
Table 1. Sources of efficacy inputs Sources Post-CT Ceritinib Pooled data from ASCEND-1 and ASCEND-3 trials7,9 Comparators Indirect comparison10,11 Post-ALKi Ceritinib Pooled data from ASCEND-1 and ASCEND-2 trials7,8 Docetaxel Shaw AT, et al. (2013)3, Ou SH, et al. (2014)13 Pemetrexed Shaw AT, et al. (2013)3, Ou SH, et al. (2014)13 BSC Shepherd FA, et al. (2005)14, Ou SH, et al. (2014)13 Model Inputs
منابع مشابه
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), a subset of epithelial lung cancers that are generally insensitive to chemotherapy. An estimated 3%-7% of NSCLC patients harbor tum...
متن کاملCrizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases
RATIONALE The treatment of non-small cell lung cancer (NSCLC) has now changed dramatically in recent years and anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitors are developing rapidly. PATIENT CONCERNS Here we reported a 57-year-old ALK-positive NSCLC man with brain metastases. DIAGNOSES A case of lung adenocarcinoma with brain metastases. INTERVENTIONS Crizotinib was administ...
متن کاملPersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
The fusion of echinoderm microtubule-associated protein-like 4 with the anaplastic lymphoma kinase (EML4-ALK) is found in 3%-7% of non-small-cell lung cancer (NSCLC) cases and confers sensitivity to crizotinib, the first United States Food and Drug Administration (FDA)-approved ALK inhibitor drug. Although crizotinib has an excellent initial therapeutic effect, acquired resistance to this drug ...
متن کاملSecond-generation ALK inhibitors: filling the non "MET" gap.
Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provide new options for the management of ALK-positive NSCLC.
متن کاملALK: a tyrosine kinase target for cancer therapy
The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL). Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC. In other tumors, ALK cop...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015